atezolizumab + bevacizumab + cisplatin + gemcitabine

Atezolizumab + bevacizumab + cisplatin + gemcitabine is a four-drug combination regimen used in oncology clinical trials for advanced biliary tract cancer (BTC)[1][5][7]. - **Atezolizumab** is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors and thereby enhancing T-cell–mediated anti-tumor immune responses[2][4][6]. - **Bevacizumab** is a monoclonal antibody targeting the vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth and metastasis[5][7]. - **Cisplatin** is a platinum-based small molecule chemotherapy which forms DNA crosslinks, leading to apoptosis of rapidly dividing tumor cells[3]. - **Gemcitabine** is a nucleoside analog small molecule chemotherapy which inhibits DNA synthesis, triggering cell death in malignancies[3]. The combination leverages immune checkpoint inhibition, anti-angiogenesis, and dual cytotoxic approaches. This regimen is being evaluated primarily for first-line treatment of advanced biliary tract cancers[1][5][7].

Other names

atezolizumab + bevacizumab + cisplatin + gemcitabineatezolizumab/bevacizumab/CisGem